Alzheimer disease (AD) is a major cause of age-related dementia. We do not fully
understand AD aetiology and pathogenesis, but oxidative damage is a key component. The …

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has
accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic …

Brain-age can be inferred from structural neuroimaging and compared to chronological age
(brain-age delta) as a marker of biological brain aging. Accelerated aging has been found in …

Background Magnetic resonance imaging (MRI) has unveiled specific alterations at different
stages of Alzheimer's disease (AD) pathophysiologic continuum constituting what has been …

Abstract Background and Objective: For early identification of Alzheimer's disease (AD)
based on multi-modal magnetic resonance imaging (MRI) data, it is important to make …

Amyloid positivity is an early indicator of Alzheimer's disease and is necessary to determine
the disease. In this study, a deep generative model is utilized to predict the amyloid positivity …

Introduction Convenient, cost‐effective tests for amyloid beta (Aβ) are needed to identify
those at higher risk for developing Alzheimer's disease (AD). This systematic review …

Previous studies have developed and explored magnetic resonance imaging (MRI)-based
machine learning models for predicting Alzheimer's disease (AD). However, limited research …

The extent to which newly developed blood-based biomarkers could reduce screening costs
in secondary prevention trials of Alzheimer's disease is mostly unexplored. We collected …

Dementia is a significant global health issue that is exacerbated by an aging population.
Imaging plays an established role in the evaluation of patients with neurocognitive disorders …